25 May 2023
News
Small Pharma Announces Significant Developments In Intellectual Property Portfolio
5 new patent grants with 3 expected upcoming patent grants in May.
News & Insights
Check out the latest company media, insights, and press releases. Delve into all the content on specific topic areas such as Company Financials.
4 May 2023
Insights
May 2023 Latest News Round-up
A highlight of recent news and events across April and May.
5 April 2023
Insights
April 2023 Company Update
A highlight of recent news and events so far.
4 April 2023
News
Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026
Patients who achieved remission within three months sustained remission to six months.
7 March 2023
News
Small Pharma announces further positive data from SPL026 Phase IIa trial in Major Depressive Disorder strengthening topline efficacy results
Statistically significant improvement in anxiety symptoms offers potential in indications beyond depression.
23 February 2023
Insights
The state of depression treatments today – Dr David Erritzoe
Dr. David Erritzoe shares his thoughts from a psychiatrist perspective.
16 February 2023
Insights
What is deuteration? Small Pharma’s Phase I Trial with SPL028 – Dr Carol Routledge
Dr. Carol Routledge discusses our SPL028 Phase I healthy volunteer trial.
15 February 2023
News
First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028
The Phase I study will compare IV and IM routes of SPL028 administration.
1 February 2023
News
Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue
Two new patents approved for issue bringing total to 16 granted patents.
31 January 2023
Insights
Consultant Psychiatrist Dr. David Erritzoe discusses our Phase IIa Study
Dr. David Erritzoe shares what the results could mean for psychiatry.